<code id='71291D279D'></code><style id='71291D279D'></style>

<acronym id='71291D279D'></acronym>

<center id='71291D279D'><center id='71291D279D'><tfoot id='71291D279D'></tfoot></center><abbr id='71291D279D'><dir id='71291D279D'><tfoot id='71291D279D'></tfoot><noframes id='71291D279D'>

<optgroup id='71291D279D'><strike id='71291D279D'><sup id='71291D279D'></sup></strike><code id='71291D279D'></code></optgroup>

<b id='71291D279D'><label id='71291D279D'><select id='71291D279D'><dt id='71291D279D'><span id='71291D279D'></span></dt></select></label></b><u id='71291D279D'></u>

~~<i id='71291D279D'><strike id='71291D279D'><tt id='71291D279D'><pre id='71291D279D'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

knowledge

author：fashion 2025-09-30 15:36:08 Page View：18

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Scientific mystery highlights the blind spots in genomics databases
Next article： Drug repurposing or repositioning? The language matters

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Drug companies' payments and gifts affect physicians' prescribing

Drug companies' payments and gifts affect physicians' prescribing

AdobeEachyear,abouthalfofallU.S.doctorsacceptmoneyorgiftsfromdruganddevicecompanies,totalingmorethan

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

RichardDrew/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl

read more